LBA8 Phase III study of cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) in previously untreated advanced renal cell carcinoma (aRCC) of IMDC intermediate or poor risk (COSMIC-313)
| Autor: | Choueiri, T.K., Powles, T.B., Albiges, L., Burotto, M., Szczylik, C., Zurawski, B., Riuz, E. Yanez, Maruzzo, M., Zaizar, A. Suarez, Fein, L.E., Schutz, F.A. Barros, Heng, D.Y.C., Wang, F., Mataveli, F., Chang, Y-L., van Kooten Losio, M., Rodriguez, C. Suarez, Motzer, R.J. |
|---|---|
| Zdroj: | In Annals of Oncology September 2022 33 Supplement 7:S1430-S1431 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|